Acrux completes Phase I trial of testosterone lotion
Wednesday, 06 October, 2004
Acrux (ASX: ACR) has completed a Phase I clinical trial of its testosterone metered-dose lotion for the treatment of hypogonadism, or low testosterone, in men.
The proof-of-concept study compared Acrux's product with the current market leader, a commercially available testosterone gel in five men with low testosterone. The trial was performed at Prince Henry's Institute of Medical Research in Melbourne, and was sponsored by Acrux subsidiary Acrux DDS.
The company will now seek advice on the appropriate regulatory path for approval in major world markets including the US, CEO Igor Gonda said.
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
